000 05900cam a2200769Ii 4500
005 20250919085810.0
006 m o d
007 cr cnu|||unuuu
008 161221s2015 enka ob 001 0 eng d
020 _a9780128014714
_q(electronic bk.)
020 _a0128014717
_q(electronic bk.)
020 _z9780128013175
029 1 _aCHBIS
_b010547903
029 1 _aCHVBK
_b341783668
029 1 _aDEBSZ
_b451526465
029 1 _aGBVCP
_b829920315
029 1 _aNLGGC
_b393524787
029 1 _aNZ1
_b16092610
029 1 _aDEBBG
_bBV043216385
035 _a(OCoLC)910159094
_z(OCoLC)910447567
035 _a(OCoLC)ocn910159094
039 9 _y12-21-2016
_zhafiz
_wmetacoll.MYUKM.updates.D20160920.T210208.sdallbooks.1 (perolehan)hafizupload21122016.mrc
_x159
040 _aNST
_beng
_erda
_epn
_cNST
_dIDEBK
_dNST
_dOPELS
_dYDXCP
_dEBLCP
_dCDX
_dABH
_dDEBSZ
_dOCLCQ
_dNST
049 _aMAIN
050 4 _aRC113.3
072 7 _aHEA
_x039040
_2bisacsh
072 7 _aMED
_x022090
_2bisacsh
082 0 4 _a616.90475
_223
245 0 0 _aNanotechnology in diagnosis, treatment and prophylaxis of infectious diseases /
_cedited by Mahendra Rai, Kateryna Kon.
264 1 _aLondon :
_bAcademic Press is an imprint of Elsevier,
_c[2015]
300 _a1 online resource :
_billustrations (some color)
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
504 _aIncludes bibliographical references and index.
505 0 _aFront Cover; Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases; Copyright Page; Contents; List of Contributors; Preface; 1 Gold and Silver Nanoparticles for Diagnostics of Infection; 1.1 Nanotechnology and Infection; 1.2 Gold and Silver NPs for Molecular Diagnostics; 1.2.1 Biomarkers; 1.3 Nanodiagnostics for Nucleic Acids; 1.3.1 Homogeneous Colorimetric Assays; 1.3.1.1 Unmodified NPs; 1.3.1.2 Cross-Linking; 1.3.1.3 Noncross-Linking; 1.3.2 Heterogeneous Detection; 1.3.2.1 Microarrays; 1.3.2.2 Lateral Flow Assays; 1.3.3 Electrochemical Assays.
505 8 _a1.3.4 Fluorescence Assays1.3.5 Raman and SERS; 1.3.6 Other; 1.4 Aptamers and Antibodies; 1.4.1 Colorimetric; 1.4.2 Electrochemical; 1.4.3 Lateral Flow Assays; 1.5 iPCR and Other Methods; 1.6 Conclusion; References; 2 Antimicrobial Models in Nanotechnology: From the Selection to Application in the Control and Treatment of Infectious Diseases; 2.1 Introduction; 2.2 Antimicrobial Susceptibility Testing Methods of NMs; 2.2.1 Broth Dilution Test; 2.2.2 Spectrophotometric Measurement; 2.2.3 Cell Counting; 2.2.4 Colorimetric and Fluorescent Assays; 2.2.5 In Vitro Infection Animal Model.
505 8 _a2.2.6 Biocidal Testing2.2.7 Antibiofilm Activity; 2.2.8 Quorum-Sensing Inhibitors; 2.2.9 Microbial Membrane Lysis; 2.2.10 Microbial Oxidative Stress; 2.2.11 Antipersister and Antidormancy Bacterial Cells; 2.2.12 Microbial Fitness; 2.3 Nanotoxicology; 2.3.1 Nano-Genotoxicology; 2.3.2 Cytotoxicity; 2.3.3 Immunotoxicity; 2.3.4 In Vitro Skin Irritation; 2.3.5 Caenorhabditis elegans Toxicity Model; 2.3.6 Nanotoxicity in Embryonic and Adult Zebrafish; 2.3.7 Bioluminescence-Based Nanotoxicity Test; 2.4 In Vitro Pharmacokinetics/Pharmacodynamic Models; 2.4.1 Particokinetics; 2.4.2 Caco-2 Permeability.
505 8 _a2.4.3 Hollow Fiber System2.5 Conclusions; References; 3 Silver Nanoparticles for the Control of Vector-Borne Infections; 3.1 Introduction; 3.2 Louse-Borne Infections and Activity of AgNPs Against Lice; 3.3 Mosquito-Borne Infections and Activity of AgNPs Against Mosquitoes; 3.4 Tick-Borne Infections and Activity of AgNPs Against Ticks; 3.5 Flies, Their Role in Transmission and Spread of Infections, and Activity of AgNPs Against Flies; 3.6 Conclusions and Future Prospects; References; 4 Magnetite Nanostructures: Trends in Anti-Infectious Therapy; 4.1 Introduction.
505 8 _a4.2 Nanoparticles with Biomedical Applications4.2.1 Design of Tailored Magnetic Nanoparticles with Applications in Microbiology; 4.2.2 Magnetite Nanoparticles Used to Control Microorganisms Attachment and Biofilm Formation; 4.2.3 The Biocompatibility of Magnetite Nanoparticles; 4.2.3.1 Biocompatibility Evaluation of Magnetite Nanoparticles at the Cellular Level; 4.2.3.2 Biocompatibility Evaluation of Magnetite Nanoparticles at Biochemical and Molecular Level; 4.2.3.3 Biocompatibility Evaluation of Magnetite Nanoparticles Using Animal Models; 4.3 Conclusions; References.
588 0 _aOnline resource; title from PDF title page (Ebsco, viewed May 29, 2015).
590 _aElsevier
_bScienceDirect All Books
650 0 _aCommunicable diseases
_xDiagnosis
_xTechnological innovations.
650 0 _aCommunicable diseases
_xTreatment
_xTechnological innovations.
650 0 _aNanomedicine.
650 1 2 _aNanotechnology
_xmethods.
650 2 2 _aCommunicable Disease Control
_xmethods.
650 2 2 _aCommunicable diseases
_xDiagnosis.
650 2 2 _aCommunicable Diseases
_xtherapy.
650 2 2 _aDrug Resistance, Microbial.
650 4 _aAntibiotics.
650 4 _aBacterial diseases
_xChemotherapy.
650 4 _aNanomedicine.
650 7 _aHEALTH & FITNESS
_xDiseases
_xContagious.
_2bisacsh
650 7 _aMEDICAL
_xInfectious Diseases.
_2bisacsh
655 4 _aElectronic books.
700 1 _aRai, Mahendra,
_eeditor.
700 1 _aKon, Kateryna Volodymyrivna,
_eeditor.
776 0 8 _iPrint version:
_aRai, Mahendra.
_tNanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases.
_dBurlington : Elsevier Science, ò015
_z9780128013175
856 4 0 _uhttps://eresourcesptsl.ukm.remotexs.co/user/login?url=http://www.sciencedirect.com/science/book/9780128013175
907 _a.b1640077x
_b2022-11-02
_c2019-11-12
942 _n0
914 _avtls003614182
998 _ae
_b2016-08-12
_cm
_dz
_feng
_genk
_y0
_z.b1640077x
999 _c613463
_d613463